Rachman Ilya M reported grant involving 500,000 derivative units of Immix Biopharma, Inc. at $0.00 for $0 on May 22, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
CEO and Chairman
CEO and Chairman
Filed May 29, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
500,000Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
500,000Direct
Trade date
May 22, 2026Grant
Filed
May 29, 2026, 5:05 PM ET7-day reporting delay
Accession
0001493152-26-026425Code A · Transaction 94177
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 7 calendar days after the transaction date.

IMMX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
IMMX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +13%1w ago +10%1d ago −3.7%
Returns since7d −12%30d +11%90d180d1y

Footnotes in full

F1: The Stock Option will vest in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer.